文献速递淋巴瘤浆细胞疾病造血干细胞移植与细胞治疗

采用无远程监测和早期细胞因子释放综合征干预策略的门诊CAR-T细胞治疗实施

Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention.
PubMed 文献 · Blood Adv · 2024-01-01

该研究纳入2022至2023年门诊接受商业化CD19或BCMA靶向CAR-T细胞治疗的血浆肿瘤患者,采用无居家远程监测、对≥1级细胞因子释放综合征(CRS)门诊给予托珠单抗的早期干预策略。58例中分别有17例(41%)、16例(38%)、9例(21%)在回输后0-3天、4-7天、8-30天住院,最常见住院原因为CAR-T相关毒性(33/42)。作者认为该策略下门诊商业化CAR-T治疗安全可行。

要点

  • 58例门诊CAR-T回输患者中,0-3天、4-7天、8-30天住院分别为17例(41%)、16例(38%)、9例(21%)。
  • 35例门诊因CRS接受托珠单抗的患者中,15例避免了住院。
  • 非复发死亡率1个月为1.7%、6个月为3.4%。

核心结论

  • 作者认为,采用无强化远程监测和早期CRS干预策略的门诊商业化CAR-T细胞治疗安全可行。

研究设计与样本

  • 研究纳入2022至2023年在门诊接受CAR-T细胞治疗的血浆肿瘤患者,采用无居家远程监测和早期CRS干预策略。
  • 患者前7至10天每天在癌症中心日间医院就诊,之后至第30天每周就诊两次。
  • 主要终点为CAR-T回输后3天、7天和30天住院率。
  • 早期CRS干预为门诊对≥1级CRS给予托珠单抗。
  • 共58例患者接受门诊CAR-T回输(33例骨髓瘤、24例淋巴瘤、1例急性淋巴细胞白血病)。

主要发现

  • 17例(41%)在回输后0至3天住院,16例(38%)在4至7天住院,9例(21%)在8至30天住院。
  • 最常见住院原因为CAR-T细胞相关毒性(33/42)。
  • 35例因CRS在门诊接受托珠单抗的患者中,15例避免了住院。
  • 非复发死亡率1个月为1.7%,6个月为3.4%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent studies demonstrating the feasibility of outpatient chimeric antigen receptor (CAR)-modified T-cell therapy administration are either restricted to CARs with 41BB costimulatory domains or use intensive at-home monitoring. We report outcomes of outpatient administration of all commercially available CD19- and B-cell maturation antigen (BCMA)-directed CAR T-cell therapy using a strategy of no remote at-home monitoring and an early cytokine release syndrome (CRS) intervention strategy. Patients with hematologic malignancies who received CAR T-cell therapy in the outpatient setting during 2022 to 2023 were included. Patients were seen daily in the cancer center day hospital for the first 7 to 10 days and then twice weekly through day 30. The primary end point was to determine 3-, 7-, and 30-day post-CAR T-cell infusion hospitalizations. Early CRS intervention involved administering tocilizumab as an outpatient for grade ≥1 CRS. Fifty-eight patients received outpatient CAR T-cell infusion (33 myeloma, 24 lymphoma, and 1 acute lymphoblastic leukemia). Of these, 17 (41%), 16 (38%), and 9 patients (21%) were admitted between days 0 to 3, 4 to 7, and 8 to 30 after CAR T-cell infusion, respectively. The most common reason for admission was CAR T-cell-related toxicities (33/42). Hospitalization was prevented in 15 of 35 patients who received tocilizumab for CRS as an outpatient. The nonrelapse mortality rates were 1.7% at 1 month and 3.4% at 6 months. In conclusion, we demonstrate that the administration of commercial CAR T-cell therapies in an outpatient setting is safe and feasible without intensive remote monitoring using an early CRS intervention strategy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Furqan F, Bhatlapenumarthi V, Dhakal B, et al. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. Blood Adv. 2024. PMID: 38889435. doi:10.1182/bloodadvances.2024013239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。